Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Melanoma
100%
Overall Survival
23%
Ipilimumab
18%
Pembrolizumab
17%
Recurrence Free Survival
16%
Neoplasm
16%
Placebo
15%
Metastatic Melanoma
14%
Castration Resistant Prostate Cancer
14%
Hazard Ratio
13%
Immunotherapy
11%
Progression Free Survival
11%
Nivolumab
10%
Melanoma Skin Cancer
10%
Phase III Trials
10%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
71%
Castration Resistant Prostate Cancer
22%
Ipilimumab
21%
Overall Survival
20%
Neoplasm
18%
Placebo
15%
Recurrence Free Survival
15%
Pembrolizumab
13%
Progression Free Survival
11%
Metastatic Melanoma
11%
Phase III Trials
9%
Nivolumab
9%
Immune Checkpoint Inhibitor
9%
Immunotherapy
8%
Monotherapy
8%
Keyphrases
Advanced Melanoma
34%
Metastatic Melanoma
20%
Melanoma Patients
20%
Ipilimumab
17%
Melanoma
16%
Stage III Melanoma
16%
Confidence Interval
15%
Placebo
15%
NKT Cells
14%
Overall Survival
14%
Anti-PD-1
14%
Melanoma Treatment
13%
Pembrolizumab
13%
Patient Registry
13%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
12%